Related references
Note: Only part of the references are listed.Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
Yinjie Gao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
Apostolia Maria Tsimberidou et al.
NPJ PRECISION ONCOLOGY (2021)
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Mulicentar Phase II Trial
Alice P. Chen et al.
JCO PRECISION ONCOLOGY (2021)
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series
Mohammad Faraz Naqvi et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer
Apostolia M. Tsimberidou et al.
CLINICAL LUNG CANCER (2020)
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
Nike Beaubier et al.
Oncotarget (2019)
Variant classification in precision oncology
Jonas Leichsenring et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodon et al.
NATURE MEDICINE (2019)
Integrated genomic profiling expands clinical options for patients with cancer
Nike Beaubier et al.
NATURE BIOTECHNOLOGY (2019)
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
Apostolia-Maria Tsimberidou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A simplified guide to randomized controlled trials
Amar Bhide et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2018)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study
Apostolia-Maria Tsimberidou et al.
JCO PRECISION ONCOLOGY (2017)
Targeted therapy in cancer
Apostolia-Maria Tsimberidou
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform
Amber Johnson et al.
DRUG DISCOVERY TODAY (2015)
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Funda Meric-Bernstam et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Funda Meric-Bernstam et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Apostolia-Maria Tsimberidou et al.
CLINICAL CANCER RESEARCH (2014)
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Apostolia-Maria Tsimberidou et al.
CLINICAL CANCER RESEARCH (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bayesian clinical trials
DA Berry
NATURE REVIEWS DRUG DISCOVERY (2006)
Share Paper
